Collection of biological samples to study systemic autoimmune diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to create a comprehensive collection of clinical and biological data from patients with systemic autoimmune diseases such as lupus, scleroderma, myositis, and vasculitis. By gathering biological samples, the study seeks to identify new biomarkers and enhance understanding of the physiopathological mechanisms underlying these conditions. The collected data will be made available to the medical and scientific communities to facilitate the development of new therapeutic strategies tailored to individual patient profiles. The study emphasizes the importance of early diagnosis and personalized treatment approaches.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with rare systemic autoimmune diseases (lupus, scleroderma, myositis for example),
* Patients with atypical presentations of documented or probable systemic autoimmune diseases,
* Patients receiving, or likely to receive new, innovative therapies (new molecule on the market, gene therapy, cell therapy, etc.).

Exclusion Criteria:

* Known anemia and hemoglobin \<10 g / dl
* Patients under protective supervision (guardianship, curators)
* Pregnant or breastfeeding woman

Where it's running

• Purpan University Hospital
  Toulouse, France Recruiting

Study contacts

• Principal investigator: Chloé BOST, MD, PhD — University Hospital, Toulouse
• Study coordinator: Chloé BOST, MD, PhD
• Email: bost.c@chu-toulouse.fr
• Phone: 5 61 77 61 44

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AlloNK® therapy combined with rituximab for treating certain autoimmune diseases

  This study is testing if a new treatment called AlloNK® combined with rituximab can help people with tough-to-treat autoimmune diseases feel better.

  Recruiting at 52 sites Phase 2 Artiva Biotherapeutics, Inc. · Tuscaloosa, Alabama and 51 other locations · NCT06991114

• Imaging markers for bulbar involvement in inclusion body myositis among IBM and comparison groups

  This study tests whether ultrasound and MRI can detect swallowing and bulbar muscle problems in people with inclusion body myositis.

  Recruiting Johns Hopkins University · Baltimore, Maryland · NCT07823101

• Long-Term Guselkumab Use in Adults with Inflammatory Bowel Disease

  This study looks at how long adults with Crohn's disease or ulcerative colitis stay on guselkumab in real-world care.

  Recruiting Janssen Research & Development, LLC · Amiens · NCT07822529

• CR-402 treatment for refractory autoimmune disease

  This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.

  Recruiting Phase 1/2 Myeloid Therapeutics · Nedlands, Western Australia · NCT07778446

• Intestinal ultrasound-guided management for inflammatory bowel disease

  This study tests if adding point-of-care intestinal ultrasound at every visit changes treatment decisions for adults with Crohn’s disease or ulcerative colitis undergoing disease assessment.

  Recruiting Mahidol University · Bangkok · NCT07775352

• Treatment Response in Myositis-Associated RP-ILD in Adults

  This study tests how people with myositis and rapidly progressing interstitial lung disease respond to an immunosuppressant treatment approach.

  Recruiting Singapore General Hospital · Singapore · NCT07775235

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.